| [1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1):7-34.
|
| [2] |
Riva F, Dronov OI, Khomenko DI, et al. Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer[J]. Mol Oncol, 2016, 10(3):481-493.
|
| [3] |
Imamura T, Komatsu S, Ichikawa D, et al. Liquid biopsy in patients with pancreatic cancer: circulating tumor cells and cell-free nucleic acids[J]. World J Gastroenterol, 2016, 22(25):5627-5641.
|
| [4] |
Qi ZH, Xu HX, Zhang SR, et al. The significance of liquid biopsy in pancreatic cancer[J]. J Cancer, 2018, 9(18):3417-3426.
|
| [5] |
Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies[J]. Sci Transl Med, 2014, 6(224):224ra24.
|
| [6] |
Melo SA, Luecke LB, Kahiert C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer[J]. Nature, 2015, 523(7559):177-182.
|
| [7] |
Yoshioka Y, Kosaka N, Konishi Y, et al. Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen[J]. Nat Commun, 2014(5):3591.
|
| [8] |
Nagrath S, Jack RM, Sahai V, et al. Opportunities and challenges for pancreatic circulating tumor cells[J]. Gastroenterology, 2016, 151(3):412-426.
|
| [9] |
Liu H, Sun B, Wang S, et al. Circulating tumor cells as a biomarker in pancreatic ductal adenocarcinoma[J]. Cell Physiol Biochem, 2017, 42(1):373-382.
|
| [10] |
Wei T, Zhang X, Zhang Q, et al. Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer[J]. Cancer Lett, 2019(452): 237-243.
|
| [11] |
Zill OA, Greene C, Sebisanovic D, et al. Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas[J]. Cancer Discov, 2015, 5(10):1040-1048.
|
| [12] |
Sausen M, Phallen J, Adleff V, et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients[J]. Nat Commun, 2015(6):7686.
|
| [13] |
Henriksen SD, Madsen PH, Larsen AC, et al. Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma[J]. Clin Epigenetics, 2016, 8(1):117.
|
| [14] |
Allenson K, Castillo J, San Lucas FA, et al. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients[J]. Ann Oncol, 2017, 28(4):741-747.
|
| [15] |
Buscail E, Chauvet A, Quincy P, et al. CD63-GPC1-positive exosomes coupled with CA19-9 offer good diagnostic potential for resectable pancreatic ductal adenocarcinoma[J]. Transl Oncol, 2019, 12(11):1395-1403.
|
| [16] |
Lai X, Wang M, Mcelyea SD, et al. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer[J]. Cancer Lett, 2017, 393:86-93.
|
| [17] |
Zhao XH, Wang ZR, Chen CL, et al. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: potential role in clinical practice[J]. World J Gastroenterol, 2019, 25(1):138-150.
|
| [18] |
Tien YW, Kuo HC, Ho BI, et al. A high circulating tumor cell count in portal vein predicts liver metastasis from periampullary or pancreatic cancer: a high portal venous CTC count predicts liver metastases[J]. Medicine, 2016, 95(16):e3407.
|
| [19] |
Poruk KE, Valero V 3rd, Saunders T, et al. Circulating tumor cell phenotype predicts recurrence and survival in pancreatic adenocarcinoma[J]. Ann Surg, 2016, 264(6):1073-1081.
|
| [20] |
Gemenetzis G, Groot VP, Yu J, et al. Circulating tumor cells dynamics in pancreatic adenocarcinoma correlate with disease status: results of the prospective CLUSTER study[J]. Ann Surg, 2018, 268(3):408-420.
|
| [21] |
Earl J, Garcia-Nieto S, Martinez-Avila JC, et al. Circulating tumor cells (CTC) and KRAS mutant circulating free DNA (cfDNA) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer[J]. BMC Cancer, 2015, 15(1):797.
|
| [22] |
Bernard V, Kim DU, San Lucas FA, et al. Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer[J]. Gastroenterology, 2019, 156(1):108-118, e4.
|
| [23] |
Lee B, Lipton L, Cohen J, et al. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer[J]. Ann Oncol, 2019, 30(9):1472-1478.
|
| [24] |
Cheng H, Liu C, Jiang J, et al. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients[J]. Int J Cancer, 2017, 140(10):2344-2350.
|